

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

VASO Corp

Form: 8-K

Date Filed: 2013-07-31

Corporate Issuer CIK: 839087

© Copyright 2018, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: July 30, 2013 (Date of earliest event reported)

VASOMEDICAL, INC.

(Exact name of registrant as specified in charter)

Delaware	0-18105	11-2871434
(State or other jurisdiction	(Commission File	(IRS Employer
of incorporation)	Number)	Identification No.)
180 Linden Avenue, Westbury, New York		11590
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code:	<u>(5</u>	16) 997-4600
(Former name or former address, if changed since last report)		
Check the appropriate box below if the Form 8-K filing is provisions (see General Instruction A.2. below):	intended to simultaneously satisfy the filing obligation	on of the registrant under any of the following
[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
Pre-commencement to communications pursua	ant to Rule 13e-4(c) under the Exchange Act (17 C	FH 240.13e-4(c))

Item 8.01 Other Events

On July 30, 2013, the Company approved an increase to its previously announced stock repurchase program of its common stock, from up to \$1.5 million to up to \$2 million. As of the close of business on July 30, 2013, the Company has acquired 7,989,258 shares of its common stock pursuant to this program, including a block transaction of 6,708,134 shares on July 30, 2013, at an aggregate cost to the Company of \$1,347,191.20.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 31, 2013 VASOMEDICAL, INC.

By: <u>/s/ Jun Ma</u> Jun Ma President and Chief Executive Officer